Human pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs) provide unprecedented opportunities for cell therapies against intractable …

Predicting the effects of drugs before human clinical trials is at the heart of drug screening
and discovery processes. The cost of drug discovery is steadily increasing owing to the …

Congenital heart defects constitute the most common human birth defect, however
understanding of how these disorders originate is limited by our ability to model the human …

Compact cardiomyocytes that make up the ventricular wall of the adult heart represent an
important therapeutic target population for modeling and treating cardiovascular diseases …

Skeletal muscle is the largest tissue in the body and loss of its function or its regenerative
properties results in debilitating musculoskeletal disorders. Understanding the mechanisms …

The ability to direct the differentiation of human pluripotent stem cells (hPSCs) to the different
cardiomyocyte subtypes is a prerequisite for modeling specific forms of cardiovascular …

Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are
efficient but require complex, undefined medium constituents that hinder further elucidation …

To curb the high cost of drug development, there is an urgent need to develop more
predictive tissue models using human cells to determine drug efficacy and safety in advance …

Embryos allocate cells to the three germ layers in a spatially ordered sequence. Human
embryonic stem cells (hESCs) can generate the three germ layers in culture; however …

The protocol described here efficiently directs human pluripotent stem cells (hPSCs) to
functional cardiomyocytes in a completely defined, growth factor–and serum-free system by …